20% off purchase of 3 or more products* | Learn More >>

Polyclonal Antibody Peptide Transporter Activity

Also showing Polyclonal Antibody Western Blotting Peptide Transporter Activity

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunoprecipitation, Western Blotting

Background: CD8+ cytotoxic T cells recognize peptides presented by MHC class I molecules on the surface of infected cells and tumor cells. The transporters associated with antigen processing 1 and 2 (TAP1 and TAP2) form the TAP complex which resides on the ER membrane and transports peptides from the cytoplasm into the ER for loading onto MHC class I molecules (1-8). In addition, TAP localized to endosomal membranes is important for cross-presentation by dendritic cells (9,10). IFN-γ produced by T cells and NK cells in response to infection causes upregulation of TAP1 and TAP2, resulting in increased antigen presentation to T cells (11). Some viral proteins inhibit TAP function or downregulate TAP expression resulting in viral immune evasion (12,13). In addition, investigators have observed reduced TAP expression in a variety of tumor types, and it is thought to be one mechanism for tumor immune evasion (14).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse

Application Methods: Western Blotting

Background: CD8+ cytotoxic T cells recognize peptides presented by MHC class I molecules on the surface of infected cells and tumor cells. The transporters associated with antigen processing 1 and 2 (TAP1 and TAP2) form the TAP complex which resides on the ER membrane and transports peptides from the cytoplasm into the ER for loading onto MHC class I molecules (1-8). In addition, TAP localized to endosomal membranes is important for cross-presentation by dendritic cells (9,10). IFN-γ produced by T cells and NK cells in response to infection causes upregulation of TAP1 and TAP2, resulting in increased antigen presentation to T cells (11). Some viral proteins inhibit TAP function or downregulate TAP expression resulting in viral immune evasion (12,13). In addition, investigators have observed reduced TAP expression in a variety of tumor types, and it is thought to be one mechanism for tumor immune evasion (14).

$260
100 µl
APPLICATIONS
REACTIVITY
Bovine, Human, Monkey, Mouse, Rat

Application Methods: Western Blotting

Background: Nucleoporin 98 kDa (NUP98) is a component of the nuclear pore complex. It is expressed as three different precursors that undergo auto-cleavage to generate a common amino-terminal 98 kDa peptide (NUP98) and carboxy-terminal 6, 96 (NUP96) and 88 (p88) kDa peptides (1,2). NUP98 contains FG and GLFG repeat domains at its amino terminus and a RNA-binding domain in its carboxy terminus (3). The NUP98 gene is localized on chromosome 11p15.5, a region frequently rearranged in leukemias. To date, 15 fusion partners have been identified for NUP98 (4,5).

$260
100 µl
APPLICATIONS
REACTIVITY
Bovine, Human, Monkey, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: Nucleoporin 98 kDa (NUP98) is a component of the nuclear pore complex. It is expressed as three different precursors that undergo auto-cleavage to generate a common amino-terminal 98 kDa peptide (NUP98) and carboxy-terminal 6, 96 (NUP96) and 88 (p88) kDa peptides (1,2). NUP98 contains FG and GLFG repeat domains at its amino terminus and a RNA-binding domain in its carboxy terminus (3). The NUP98 gene is localized on chromosome 11p15.5, a region frequently rearranged in leukemias. To date, 15 fusion partners have been identified for NUP98 (4,5).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunoprecipitation, Western Blotting

Background: L-type amino acid transporter 1 (LAT1), also known as Solute carrier family 7 member 5 (SLC7A5), is a high-affinity neutral transporter of larger amino acids. It facilitates the cellular amino acid uptake in a sodium independent manner (1-2) and selectively transports D-and L-isomers of small neutral amino acids (3). LAT1 also regulates amino acid exchange in conjunction with solute carrier family 1 member 5 (SLC1A5) (2,4-6). Transport of thyroid hormones across the placenta is established via LAT1 during normal fetal development (7). LAT1 promotes neuronal cell proliferation by regulating the transport of amino acids across the blood brain barrier (8). LAT1 is upregulated in various cancer types including breast cancer, lung cancer, prostate cancer, and gliomas (9,10). High expression of LAT1 is detected in non-small cell lung cancer with lymph node metastases(9,11,12). Increased LAT1 expression is a novel biomarker of high grade malignancy in prostate cancers (12). Inhibition of LAT1 suppresses tumor cell growth in several tumor types (10,13).